What's in LEO Pharma's pipeline?

LEO Pharma has 107 drugs in our index: 15 marketed, 0 filed, 31 in Phase 3, 29 in Phase 2, 30 in Phase 1.

Which companies overlap with LEO Pharma's portfolio?

Top competitors by shared drug class: Galderma R&D, Pfizer, GlaxoSmithKline, Stiefel, a GSK Company, Actavis Inc..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/leo-pharma.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-13 · How we verify

LEO Pharma — Portfolio Competitive Intelligence Brief

LEO Pharma pipeline: 15 marketed, 0 filed, 31 Phase 3, 29 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

15 marketed 0 filed 31 Phase 3 29 Phase 2 30 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Xamiol® Gel	Xamiol® Gel	marketed	Combination topical agent (vitamin D analog + corticosteroid)	Vitamin D receptor (VDR) and glucocorticoid receptor (GR)	Dermatology
Azelaic Acid Cream	Azelaic Acid Cream	marketed	Topical antimicrobial and anti-inflammatory agent		Dermatology
Doxycycline (Oracea)	Doxycycline (Oracea)	marketed	Tetracycline antibiotic (anti-inflammatory formulation)	Matrix metalloproteinases (MMPs); 30S ribosomal subunit	Dermatology
Metronidazole (Metrogel)	Metronidazole (Metrogel)	marketed	Nitroimidazole antibiotic	Bacterial/parasitic DNA	Dermatology; Infectious Disease
innohep®	innohep®	marketed	Low-molecular-weight heparin (LMWH)	Antithrombin III (enhancer); Factor Xa and Thrombin (indirect targets)	Cardiovascular
Diclofenac sodium gel 3%	Diclofenac sodium gel 3%	marketed	NSAID (nonsteroidal anti-inflammatory drug)	COX-1 and COX-2 (cyclooxygenase enzymes)	Pain management / Rheumatology
Topical suspension vehicle	Topical suspension vehicle	marketed			Dermatology
Calcipotriol plus betamethasone dipropionate ointment	Calcipotriol plus betamethasone dipropionate ointment	marketed
Pimecrolimus cream	Pimecrolimus cream	marketed
Elidel®	Elidel®	marketed
Ingenol Mebutate Gel, 0.015%	Ingenol Mebutate Gel, 0.015%	marketed
Fucidin® cream	Fucidin® cream	marketed	Steroid antibiotic	Bacterial elongation factor G (EF-G)	Dermatology / Infectious Disease

Therapeutic area mix

Dermatology · 45
Other · 3
Respiratory · 2
Cardiovascular · 1
Immunology · 1
Pain management / Rheumatology · 1
Dermatology; Infectious Disease · 1
Dermatology / Immunology · 1
Dermatology / Infectious Disease · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Galderma R&D · 8 shared drug classes
Pfizer · 6 shared drug classes
GlaxoSmithKline · 5 shared drug classes
Stiefel, a GSK Company · 4 shared drug classes
Actavis Inc. · 4 shared drug classes
Bausch Health Americas, Inc. · 4 shared drug classes
Federal University of São Paulo · 4 shared drug classes
Allergan · 3 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for LEO Pharma:

Cite this brief

Drug Landscape (2026). LEO Pharma — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/leo-pharma. Accessed 2026-05-13.